• Powered by Crown Equity Holdings Inc.
      • crown-logo

        Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Post on CRWE World Login
logo Fairfield, UNITED STATES
header-img
  • Home
  • News
  • World
      • World News
      • Español
  • Politics
      • U.S. Legislators
      • Political News
  • Sports
  • Business
      • Markets
      • Hottest Stocks Today
      • CRWEWorld Stocks
      • Blockchain
      • Regulatory
      • Accounting
      • Fundraising Campaigns
      • IPOs
      • Money
      • Career
  • Tech
      • Tech
      • Science
  • Living
      • Arts & Entertainment
      • Family
      • Food
      • Pets
      • Seniors
      • Fashion/Fitness
      • Home & Garden
  • Health
      • Health
      • Pharma & Biotech
  • Opinion
      • Finance
      • Law
      • Healthcare
      • Cannabidiol (CBD)
      • Fashion
      • Podcasts
      • Tech
      • Music
  • Travel
  • Local
      • News
      • Trending Now
      • Real Estate
      • Coupons & Deals
      • Business Directory
  • Jobs
  • More
      • Business 2 Business
      • Press Releases
      • Press Releases Pricing
      • News from GlobeNewswire
      • News from PR Newswire
      • News from Business Wire
      • News from Accesswire
      • Video Channels
      • Beauty
      • Business
      • Comedy
      • Entertainment
      • Fashion
      • Featured
      • Health
      • Instructional
      • News
      • Politics
      • Sports
      • Technology
      • Entertainment
      • Horoscope
      • Sudoku
      • Crossword
      • Games
      • Chat
      • Affiliate | How It Works
      • Join CRWE WORLD Affiliate Program
      • CRWE WORLD Advertising Services Rate
      • Crown Equity Holdings' Overview
      • CRWEWorld Real-Time Global Visitors
      • Content Delivery Solution
        • Contact Us
  • More

Change City


-- OR --
load
load
/assets/img/hottest3.png
/assets/img/hottest2.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png
  • Home
  • Articles
  • News Provided by PR Newswire
21ьз╕ Cweather-icon
/assets/img/hottest3.png
/assets/img/hottest2.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png

GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain

News Provided by PR Newswire2018-06-25
7 Views

GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain

The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures.

 
[25-June-2018]
 

LAS VEGAS, June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has filed nonprovisional patent applications to protect its myrcene-containing complex mixtures ("MCCC") for the treatment of chronic pain and heart disorders. These new US and PCT international applications claim the benefit of GB Sciences' provisional application previously filed on May 22nd, 2017, supplying additional data from patch-clamp studies on individual cells that further support their claims. Novel pain treatments are a promising field of research and development given concerns regarding opioid usage and potential for abuse. The Company's novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol ("THC"), which minimizes their potential for abuse. Pain represents an estimated health burden of between $560 and 650 billion dollars for chronic pain and between $17 and $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, these novel cardiac formulations address the $316 billion-dollar cardiac therapy market in the US.

(PRNewsfoto/GB Sciences, Inc.)

"GB Sciences' myrcene-containing complex mixtures for heart disease and chronic pain leverage powerful molecular synergies between specific complex formulations of active ingredients derived from the cannabis plants including many terpenes and minor cannabinoids," said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc. "Our formulations capture whole plant medicine's benefits, but they are further optimized and standardized. In preclinical studies, these complex mixtures have a greater therapeutic potential than the sums of the therapeutic effects of the individual ingredients. Other companies are creating cannabis-based therapeutics primarily based on one or two major cannabinoids, but our data suggests that complex formulations targeting specific diseases containing as many as a dozen ingredients provide greater potential clinical benefits than single- or double-active ingredient formulas."

The Company's drug discovery efforts were accelerated through the powerful combination of GB Sciences' proprietary in silico prediction approach, termed the GB Sciences' Network Pharmacology Platform ("NPP"), and GB Sciences' proven high-throughput screening techniques using cell-based models of pain and heart disease. The current nonprovisional patent application covers myrcene-containing complex mixtures that are capable of targeting the non-traditional cannabinoid receptor, TRPV1. The latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016.

"GB Sciences is developing these pain and heart formulas in accordance with our strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC," explains John Poss, Chairman and CEO of GB Sciences, Inc. "In addition, we are creating time-released forms of these formulations through our joint nanotech research program with the University of Seville. Our commitment to providing novel therapies and improved delivery methods will be tested in a pilot human trial in 2019."

About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information
Corporate:  GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or Tom Arcuragi, EVP, tom@gbsciences.com
www.gbsciences.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-files-patents-for-heart-disease-and-chronic-immunological-and-neuropathic-pain-300671287.html

SOURCE GB Sciences, Inc.


Company Codes: OTC-QB:GBLX, OTC-PINK:GBLX


© 2018 PR Newswire. All Rights Reserved.

#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.


Berkshire Hathaway Inc. (NYSE: BRK.A) (NYSE: BRK.B) Reports Fourth Quarter and Full Year 2020



/assets/img/cw-stocks.png

/assets/img/wysh-jewels.png

/assets/img/hjli.png

/assets/img/Mars-Parachute-2.png

/assets/img/crweworld-podcast.jpg
Sponsored
Also read
18 reportedly killed in Myanmar anti-coup protests; Canadian Embassy condemns crackdown
Admiral Markets AS unaudited 12 months financial results of 2020
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
4 reported killed in Myanmar anti-coup protests, held in multiple cities
Comenius, el visionario que se inventó la educación moderna hace 400 años (y las tareas que nos quedan por hacer)
El superfertilizante natural que le permitió a una civilización preincaica prosperar en el árido desierto de Atacama en Chile
Doctor joins Zoom court hearing while operating on patient
Coronavirus: cómo los pacientes excepcionales exponen los puntos débiles del SARS-CoV-2


Post on CRWE WorldSign Up for Free E-mail Updates
  • Real Estate Eagle Firm, Real Estate
  • Hancock Jaffe Laboratories, Nasdaq:HJLI, HJLI
Signup for free email updates
/assets/img/wall-street-rect2.png
/assets/img/wall-street-sq.png



Join with us
Live Traffic Feed
About CrweWorld
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Finance Disclaimer
  • Jobs
Subscribe for newsletter
3+2
Contact Info
  • contact@crweworld.com

  • P: (702) 683-8946

  • P: (702) 810-0178

  • 11226 Pentland Downs St, Las Vegas, NV 89141

Tweets by CrweWorld
Tweets by @CrweWorld
  • © 2021 crweworld.com
ad1

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

ad3

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

ad5

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

Advertisements

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

CRWE WORLD Advertising Services RateJoin CRWE WORLD Affiliate Program